Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.37 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6178736 | 0.85 | TGFBR1 (0.38) | MEN1KMT2AATMMDM2TGFBR1 | |
| SCHEMBL6183901 | 0.85 | KDM1A (0.40) | MEN1KMT2AATM | |
| SCHEMBL6180753 | 0.78 | TGFBR1 (0.40) | MEN1KMT2AATMMAPK14TGFBR1 | |
| SCHEMBL6183282 | 0.78 | IDO1 (0.45) | MAPK14FYNTGFBR1TP53 | |
| SCHEMBL6183430 | 0.73 | TGFBR1 (0.41) | MEN1KMT2AATMMAPK14TGFBR1 | |
| SCHEMBL4075747 | 0.69 | MEN1 (0.46) | MEN1KMT2AATMMAPK14SQOR | |
| SCHEMBL6483937 | 0.69 | TGFBR1 (0.40) | ATMMAPK14TGFBR1 | |
| SCHEMBL6183426 | 0.67 | KMT2A (0.36) | MEN1KMT2AATMMAPK14TGFBR1 | |
| SCHEMBL3265486 | 0.67 | CCR1 (0.54) | TGFBR1 | |
| SCHEMBL21083355 | 0.66 | EGLN2 (0.49) | TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6906089-B2 | Triarylimidazole derivatives as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1268465-B1 | TRIARYLIMIDAZOLE DERIVATIVES AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20030149277-A1 | Triarylimidazole derivatives as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-08-07 | — | — | US | disclosed |
| EP-1268465-A1 | TRIARYLIMIDAZOLE DERIVATIVES AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001072737-A1 | TRIARYLIMIDAZOLE DERIVATIVES AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149277-A1 | Triarylimidazole derivatives as cytokine inhibitors | IL2, IL2RA, IL6ST | MEN1 3492/4885KMT2A 3101/4885ATM 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.